#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Understanding mechanisms of viral strategy to evade from host antiviral responses is critical for elucidation of the pathogenesis of CSFV infection .
2-1	14-27	Understanding	_	_	_	_
2-2	28-38	mechanisms	abstract[2]	new[2]	_	_
2-3	39-41	of	abstract[2]	new[2]	_	_
2-4	42-47	viral	abstract[2]|abstract[3]	new[2]|new[3]	coref	11-31[92_3]
2-5	48-56	strategy	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-6	57-59	to	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-7	60-65	evade	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-8	66-70	from	abstract[2]|abstract[3]	new[2]|new[3]	_	_
2-9	71-75	host	abstract[2]|abstract[3]|person|abstract[5]	new[2]|new[3]|new|new[5]	coref	9-12[66_5]
2-10	76-85	antiviral	abstract[2]|abstract[3]|abstract[5]	new[2]|new[3]|new[5]	_	_
2-11	86-95	responses	abstract[2]|abstract[3]|abstract[5]	new[2]|new[3]|new[5]	_	_
2-12	96-98	is	_	_	_	_
2-13	99-107	critical	_	_	_	_
2-14	108-111	for	_	_	_	_
2-15	112-123	elucidation	event[6]	new[6]	_	_
2-16	124-126	of	event[6]	new[6]	_	_
2-17	127-130	the	event[6]|abstract[7]	new[6]|new[7]	_	_
2-18	131-143	pathogenesis	event[6]|abstract[7]	new[6]|new[7]	_	_
2-19	144-146	of	event[6]|abstract[7]	new[6]|new[7]	_	_
2-20	147-151	CSFV	event[6]|abstract[7]|abstract|event[9]	new[6]|new[7]|new|new[9]	coref|coref	4-1|10-14[74_9]
2-21	152-161	infection	event[6]|abstract[7]|event[9]	new[6]|new[7]|new[9]	_	_
2-22	162-163	.	_	_	_	_

#Text=Type I IFNs represent one of the first lines of defense of the innate immune system and are produced rapidly upon recognition of viral factors by PRRs .
3-1	164-168	Type	abstract[10]|abstract[11]	new[10]|new[11]	coref|coref	4-10[21_10]|4-10[22_11]
3-2	169-170	I	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-3	171-175	IFNs	abstract[11]	new[11]	_	_
3-4	176-185	represent	_	_	_	_
3-5	186-189	one	abstract[12]	new[12]	_	_
3-6	190-192	of	abstract[12]	new[12]	_	_
3-7	193-196	the	abstract[12]|abstract[13]	new[12]|new[13]	coref	18-1[149_13]
3-8	197-202	first	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-9	203-208	lines	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-10	209-211	of	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-11	212-219	defense	abstract[12]|abstract[13]|abstract[14]	new[12]|new[13]|new[14]	_	_
3-12	220-222	of	abstract[12]|abstract[13]|abstract[14]	new[12]|new[13]|new[14]	_	_
3-13	223-226	the	abstract[12]|abstract[13]|abstract[14]|abstract[15]	new[12]|new[13]|new[14]|new[15]	_	_
3-14	227-233	innate	abstract[12]|abstract[13]|abstract[14]|abstract[15]	new[12]|new[13]|new[14]|new[15]	_	_
3-15	234-240	immune	abstract[12]|abstract[13]|abstract[14]|abstract[15]	new[12]|new[13]|new[14]|new[15]	_	_
3-16	241-247	system	abstract[12]|abstract[13]|abstract[14]|abstract[15]	new[12]|new[13]|new[14]|new[15]	_	_
3-17	248-251	and	_	_	_	_
3-18	252-255	are	_	_	_	_
3-19	256-264	produced	_	_	_	_
3-20	265-272	rapidly	_	_	_	_
3-21	273-277	upon	_	_	_	_
3-22	278-289	recognition	event[16]	new[16]	_	_
3-23	290-292	of	event[16]	new[16]	_	_
3-24	293-298	viral	event[16]|abstract[17]	new[16]|new[17]	_	_
3-25	299-306	factors	event[16]|abstract[17]	new[16]|new[17]	_	_
3-26	307-309	by	_	_	_	_
3-27	310-314	PRRs	abstract	new	_	_
3-28	315-316	.	_	_	_	_

#Text=CSFV is known to interfere with the generation of type I IFNs by inducing proteasomal degradation of IRF3 .
4-1	317-321	CSFV	abstract	giv	coref	6-12
4-2	322-324	is	_	_	_	_
4-3	325-330	known	_	_	_	_
4-4	331-333	to	_	_	_	_
4-5	334-343	interfere	_	_	_	_
4-6	344-348	with	_	_	_	_
4-7	349-352	the	event[20]	new[20]	_	_
4-8	353-363	generation	event[20]	new[20]	_	_
4-9	364-366	of	event[20]	new[20]	_	_
4-10	367-371	type	event[20]|abstract[21]|abstract[22]	new[20]|giv[21]|giv[22]	coref|coref	5-1[25_21]|5-1[26_22]
4-11	372-373	I	event[20]|abstract[21]|abstract[22]	new[20]|giv[21]|giv[22]	_	_
4-12	374-378	IFNs	event[20]|abstract[22]	new[20]|giv[22]	_	_
4-13	379-381	by	_	_	_	_
4-14	382-390	inducing	_	_	_	_
4-15	391-402	proteasomal	event[23]	new[23]	_	_
4-16	403-414	degradation	event[23]	new[23]	_	_
4-17	415-417	of	event[23]	new[23]	_	_
4-18	418-422	IRF3	event[23]|abstract	new[23]|new	coref	25-16
4-19	423-424	.	_	_	_	_

#Text=Type III IFNs play a critical role in antiviral innate immunity in mucosal epithelial cells .
5-1	425-429	Type	abstract[25]|abstract[26]	giv[25]|giv[26]	coref|coref	6-14[32_25]|9-14[0_26]
5-2	430-433	III	abstract[25]|abstract[26]	giv[25]|giv[26]	_	_
5-3	434-438	IFNs	abstract[26]	giv[26]	_	_
5-4	439-443	play	_	_	_	_
5-5	444-445	a	abstract[27]	new[27]	_	_
5-6	446-454	critical	abstract[27]	new[27]	_	_
5-7	455-459	role	abstract[27]	new[27]	_	_
5-8	460-462	in	abstract[27]	new[27]	_	_
5-9	463-472	antiviral	abstract[27]|abstract[28]	new[27]|new[28]	_	_
5-10	473-479	innate	abstract[27]|abstract[28]	new[27]|new[28]	_	_
5-11	480-488	immunity	abstract[27]|abstract[28]	new[27]|new[28]	_	_
5-12	489-491	in	abstract[27]|abstract[28]	new[27]|new[28]	_	_
5-13	492-499	mucosal	abstract[27]|abstract[28]|object[29]	new[27]|new[28]|new[29]	coref	11-15[88_29]
5-14	500-510	epithelial	abstract[27]|abstract[28]|object[29]	new[27]|new[28]|new[29]	_	_
5-15	511-516	cells	abstract[27]|abstract[28]|object[29]	new[27]|new[28]|new[29]	_	_
5-16	517-518	.	_	_	_	_

#Text=However , little information is available as to whether and how CSFV modulates type III IFN response .
6-1	519-526	However	_	_	_	_
6-2	527-528	,	_	_	_	_
6-3	529-535	little	abstract[30]	new[30]	_	_
6-4	536-547	information	abstract[30]	new[30]	_	_
6-5	548-550	is	_	_	_	_
6-6	551-560	available	_	_	_	_
6-7	561-563	as	_	_	_	_
6-8	564-566	to	_	_	_	_
6-9	567-574	whether	_	_	_	_
6-10	575-578	and	_	_	_	_
6-11	579-582	how	_	_	_	_
6-12	583-587	CSFV	abstract	giv	coref	7-10
6-13	588-597	modulates	_	_	_	_
6-14	598-602	type	abstract[32]|abstract[35]	giv[32]|new[35]	coref|coref	7-13[40_32]|10-25[78_35]
6-15	603-606	III	abstract[32]|person|abstract[35]	giv[32]|new|new[35]	coref	9-13
6-16	607-610	IFN	abstract|abstract[35]	new|new[35]	coref	20-12
6-17	611-619	response	abstract[35]	new[35]	_	_
6-18	620-621	.	_	_	_	_

#Text=The present study demonstrates that the Npro protein of CSFV inhibited IRF1-mediated type III IFNs production by down-regulation of IRF1 expression and blockage of its nuclear translocation .
7-1	622-625	The	abstract[36]	new[36]	coref	8-30[59_36]
7-2	626-633	present	abstract[36]	new[36]	_	_
7-3	634-639	study	abstract[36]	new[36]	_	_
7-4	640-652	demonstrates	_	_	_	_
7-5	653-657	that	_	_	_	_
7-6	658-661	the	substance[38]	new[38]	ana	7-25[0_38]
7-7	662-666	Npro	object|substance[38]	new|new[38]	coref	8-15[55_0]
7-8	667-674	protein	substance[38]	new[38]	_	_
7-9	675-677	of	substance[38]	new[38]	_	_
7-10	678-682	CSFV	substance[38]|abstract	new[38]|giv	coref	8-15
7-11	683-692	inhibited	_	_	_	_
7-12	693-706	IRF1-mediated	abstract[42]	new[42]	_	_
7-13	707-711	type	abstract[40]|abstract[42]	giv[40]|new[42]	coref	9-12[63_40]
7-14	712-715	III	abstract[40]|abstract[42]	giv[40]|new[42]	_	_
7-15	716-720	IFNs	abstract|abstract[42]	new|new[42]	_	_
7-16	721-731	production	abstract[42]	new[42]	_	_
7-17	732-734	by	_	_	_	_
7-18	735-750	down-regulation	abstract[43]	new[43]	_	_
7-19	751-753	of	abstract[43]	new[43]	_	_
7-20	754-758	IRF1	abstract[43]|abstract|abstract[45]	new[43]|new|new[45]	coref	27-1
7-21	759-769	expression	abstract[43]|abstract[45]	new[43]|new[45]	_	_
7-22	770-773	and	abstract[43]	new[43]	_	_
7-23	774-782	blockage	abstract[43]|object[46]	new[43]|new[46]	_	_
7-24	783-785	of	abstract[43]|object[46]	new[43]|new[46]	_	_
7-25	786-789	its	abstract[43]|object[46]|substance|abstract[48]	new[43]|new[46]|giv|new[48]	coref	19-28[170_0]
7-26	790-797	nuclear	abstract[43]|object[46]|abstract[48]	new[43]|new[46]|new[48]	_	_
7-27	798-811	translocation	abstract[43]|object[46]|abstract[48]	new[43]|new[46]|new[48]	_	_
7-28	812-813	.	_	_	_	_

#Text=The Npro-deleted mutant showed similar growth kinetics to its parental strain , indicating that CSFV Npro does not alter the replication in cell culture , which is consistent with the previous study .
8-1	814-817	The	animal[49]	new[49]	ana	8-9[0_49]
8-2	818-830	Npro-deleted	animal[49]	new[49]	_	_
8-3	831-837	mutant	animal[49]	new[49]	_	_
8-4	838-844	showed	_	_	_	_
8-5	845-852	similar	abstract[51]	new[51]	_	_
8-6	853-859	growth	abstract|abstract[51]	new|new[51]	_	_
8-7	860-868	kinetics	abstract[51]	new[51]	_	_
8-8	869-871	to	_	_	_	_
8-9	872-875	its	animal|abstract[53]	giv|new[53]	coref|coref	19-4[161_0]|19-22[168_53]
8-10	876-884	parental	abstract[53]	new[53]	_	_
8-11	885-891	strain	abstract[53]	new[53]	_	_
8-12	892-893	,	_	_	_	_
8-13	894-904	indicating	_	_	_	_
8-14	905-909	that	_	_	_	_
8-15	910-914	CSFV	abstract|object[55]	giv|giv[55]	coref|coref	11-6|19-29[0_55]
8-16	915-919	Npro	object[55]	giv[55]	_	_
8-17	920-924	does	_	_	_	_
8-18	925-928	not	_	_	_	_
8-19	929-934	alter	_	_	_	_
8-20	935-938	the	abstract[56]	new[56]	_	_
8-21	939-950	replication	abstract[56]	new[56]	_	_
8-22	951-953	in	_	_	_	_
8-23	954-958	cell	object|abstract[58]	new|new[58]	coref	13-11
8-24	959-966	culture	abstract[58]	new[58]	_	_
8-25	967-968	,	_	_	_	_
8-26	969-974	which	_	_	_	_
8-27	975-977	is	_	_	_	_
8-28	978-988	consistent	_	_	_	_
8-29	989-993	with	_	_	_	_
8-30	994-997	the	abstract[59]	giv[59]	coref	17-10[147_59]
8-31	998-1006	previous	abstract[59]	giv[59]	_	_
8-32	1007-1012	study	abstract[59]	giv[59]	_	_
8-33	1013-1014	.	_	_	_	_

#Text=Some viruses have evolved to encode viral antagonists for evasion of type III IFNs responses .
9-1	1015-1019	Some	animal[60]	new[60]	coref	27-8[244_60]
9-2	1020-1027	viruses	animal[60]	new[60]	_	_
9-3	1028-1032	have	_	_	_	_
9-4	1033-1040	evolved	_	_	_	_
9-5	1041-1043	to	_	_	_	_
9-6	1044-1050	encode	_	_	_	_
9-7	1051-1056	viral	person[61]	new[61]	_	_
9-8	1057-1068	antagonists	person[61]	new[61]	_	_
9-9	1069-1072	for	_	_	_	_
9-10	1073-1080	evasion	event[62]	new[62]	_	_
9-11	1081-1083	of	event[62]	new[62]	_	_
9-12	1084-1088	type	event[62]|abstract[63]|abstract[66]	new[62]|giv[63]|giv[66]	coref	10-8[0_63]
9-13	1089-1092	III	event[62]|abstract[63]|person|abstract[66]	new[62]|giv[63]|giv|giv[66]	coref	12-8
9-14	1093-1097	IFNs	event[62]|abstract|abstract[66]	new[62]|giv|giv[66]	coref	10-8[71_0]
9-15	1098-1107	responses	event[62]|abstract[66]	new[62]|giv[66]	_	_
9-16	1108-1109	.	_	_	_	_

#Text=Reid et al showed the induction of type III IFNs in pDCs upon BVDV infection , and type III IFNs contributed to suppression of cellular immune response during BVDV infection .
10-1	1110-1114	Reid	person	new	_	_
10-2	1115-1117	et	_	_	_	_
10-3	1118-1120	al	person	new	coref	11-3
10-4	1121-1127	showed	_	_	_	_
10-5	1128-1131	the	event[69]	new[69]	_	_
10-6	1132-1141	induction	event[69]	new[69]	_	_
10-7	1142-1144	of	event[69]	new[69]	_	_
10-8	1145-1149	type	event[69]|abstract|abstract[71]	new[69]|giv|giv[71]	coref|coref	10-18[75_0]|10-18[76_71]
10-9	1150-1153	III	event[69]|abstract[71]	new[69]|giv[71]	_	_
10-10	1154-1158	IFNs	event[69]|abstract[71]	new[69]|giv[71]	_	_
10-11	1159-1161	in	event[69]|abstract[71]	new[69]|giv[71]	_	_
10-12	1162-1166	pDCs	event[69]|abstract[71]|abstract	new[69]|giv[71]|new	_	_
10-13	1167-1171	upon	_	_	_	_
10-14	1172-1176	BVDV	object|event[74]	new|giv[74]	coref|coref	10-29|10-29[80_74]
10-15	1177-1186	infection	event[74]	giv[74]	_	_
10-16	1187-1188	,	_	_	_	_
10-17	1189-1192	and	_	_	_	_
10-18	1193-1197	type	abstract[75]|abstract[76]	giv[75]|giv[76]	coref|coref	11-11[85_75]|11-11[86_76]
10-19	1198-1201	III	abstract[75]|abstract[76]	giv[75]|giv[76]	_	_
10-20	1202-1206	IFNs	abstract[76]	giv[76]	_	_
10-21	1207-1218	contributed	_	_	_	_
10-22	1219-1221	to	_	_	_	_
10-23	1222-1233	suppression	event[77]	new[77]	_	_
10-24	1234-1236	of	event[77]	new[77]	_	_
10-25	1237-1245	cellular	event[77]|abstract[78]	new[77]|giv[78]	coref	16-10[143_78]
10-26	1246-1252	immune	event[77]|abstract[78]	new[77]|giv[78]	_	_
10-27	1253-1261	response	event[77]|abstract[78]	new[77]|giv[78]	_	_
10-28	1262-1268	during	_	_	_	_
10-29	1269-1273	BVDV	object|event[80]	giv|giv[80]	coref	12-12[103_80]
10-30	1274-1283	infection	event[80]	giv[80]	_	_
10-31	1284-1285	.	_	_	_	_

#Text=Cai et al shows that CSFV induced the expression of type III IFNs in PK-15 cells , but with a limited level of increase , suggesting that CSFV might have a strategy to suppress expression of type III IFNs .
11-1	1286-1289	Cai	person	new	coref	12-38
11-2	1290-1292	et	_	_	_	_
11-3	1293-1295	al	person	giv	coref	12-40
11-4	1296-1301	shows	_	_	_	_
11-5	1302-1306	that	_	_	_	_
11-6	1307-1311	CSFV	abstract	giv	coref	11-28
11-7	1312-1319	induced	_	_	_	_
11-8	1320-1323	the	abstract[84]	new[84]	_	_
11-9	1324-1334	expression	abstract[84]	new[84]	_	_
11-10	1335-1337	of	abstract[84]	new[84]	_	_
11-11	1338-1342	type	abstract[84]|abstract[85]|abstract[86]	new[84]|giv[85]|giv[86]	coref|coref	11-37[94_85]|11-37[95_86]
11-12	1343-1346	III	abstract[84]|abstract[85]|abstract[86]	new[84]|giv[85]|giv[86]	_	_
11-13	1347-1351	IFNs	abstract[84]|abstract[86]	new[84]|giv[86]	_	_
11-14	1352-1354	in	_	_	_	_
11-15	1355-1360	PK-15	time|object[88]	new|giv[88]	coref	12-15[105_88]
11-16	1361-1366	cells	object[88]	giv[88]	_	_
11-17	1367-1368	,	_	_	_	_
11-18	1369-1372	but	_	_	_	_
11-19	1373-1377	with	_	_	_	_
11-20	1378-1379	a	abstract[89]	new[89]	coref	12-19[107_89]
11-21	1380-1387	limited	abstract[89]	new[89]	_	_
11-22	1388-1393	level	abstract[89]	new[89]	_	_
11-23	1394-1396	of	abstract[89]	new[89]	_	_
11-24	1397-1405	increase	abstract[89]|event	new[89]|new	_	_
11-25	1406-1407	,	_	_	_	_
11-26	1408-1418	suggesting	_	_	_	_
11-27	1419-1423	that	_	_	_	_
11-28	1424-1428	CSFV	abstract	giv	coref	14-2
11-29	1429-1434	might	_	_	_	_
11-30	1435-1439	have	_	_	_	_
11-31	1440-1441	a	abstract[92]	giv[92]	_	_
11-32	1442-1450	strategy	abstract[92]	giv[92]	_	_
11-33	1451-1453	to	abstract[92]	giv[92]	_	_
11-34	1454-1462	suppress	abstract[92]	giv[92]	_	_
11-35	1463-1473	expression	abstract[92]|abstract[93]	giv[92]|new[93]	coref	19-35[171_93]
11-36	1474-1476	of	abstract[92]|abstract[93]	giv[92]|new[93]	_	_
11-37	1477-1481	type	abstract[92]|abstract[93]|abstract[94]|abstract[95]	giv[92]|new[93]|giv[94]|giv[95]	coref|coref	12-7[0_94]|12-9[0_95]
11-38	1482-1485	III	abstract[92]|abstract[93]|abstract[94]|abstract[95]	giv[92]|new[93]|giv[94]|giv[95]	_	_
11-39	1486-1490	IFNs	abstract[92]|abstract[93]|abstract[95]	giv[92]|new[93]|giv[95]	_	_
11-40	1491-1492	.	_	_	_	_

#Text=We also found limited up-regulation of type III IFNs transcription upon wtCSFV infection in IPEC-J2 cells , though the transcription level peaked at 24 hpi and decreased thereafter , which is different from the results shown by Cai et al that the mRNA level of IFN-λ1 and IFN-λ3 induced by wtCSFV peaked at 36 and 48 hpi , respectively .
12-1	1493-1495	We	person	acc	ana	13-1
12-2	1496-1500	also	_	_	_	_
12-3	1501-1506	found	_	_	_	_
12-4	1507-1514	limited	abstract[97]	new[97]	_	_
12-5	1515-1528	up-regulation	abstract[97]	new[97]	_	_
12-6	1529-1531	of	abstract[97]	new[97]	_	_
12-7	1532-1536	type	abstract[97]|abstract|abstract[101]	new[97]|giv|new[101]	coref|coref	12-20[0_101]|16-6[139_0]
12-8	1537-1540	III	abstract[97]|person|abstract[101]	new[97]|giv|new[101]	coref	19-38
12-9	1541-1545	IFNs	abstract[97]|abstract|abstract[101]	new[97]|giv|new[101]	coref	16-6[140_0]
12-10	1546-1559	transcription	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-11	1560-1564	upon	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-12	1565-1571	wtCSFV	abstract[97]|abstract[101]|abstract|event[103]	new[97]|new[101]|new|giv[103]	coref|coref	12-51|15-20[0_103]
12-13	1572-1581	infection	abstract[97]|abstract[101]|event[103]	new[97]|new[101]|giv[103]	_	_
12-14	1582-1584	in	abstract[97]|abstract[101]|event[103]	new[97]|new[101]|giv[103]	_	_
12-15	1585-1592	IPEC-J2	abstract[97]|abstract[101]|event[103]|substance|object[105]	new[97]|new[101]|giv[103]|new|giv[105]	coref|coref	15-2|15-7[131_105]
12-16	1593-1598	cells	abstract[97]|abstract[101]|event[103]|object[105]	new[97]|new[101]|giv[103]|giv[105]	_	_
12-17	1599-1600	,	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-18	1601-1607	though	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-19	1608-1611	the	abstract[97]|abstract[101]|abstract[107]	new[97]|new[101]|giv[107]	_	_
12-20	1612-1625	transcription	abstract[97]|abstract[101]|abstract|abstract[107]	new[97]|new[101]|giv|giv[107]	coref	19-8[162_0]
12-21	1626-1631	level	abstract[97]|abstract[101]|abstract[107]	new[97]|new[101]|giv[107]	_	_
12-22	1632-1638	peaked	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-23	1639-1641	at	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-24	1642-1644	24	abstract[97]|abstract[101]|abstract[108]	new[97]|new[101]|new[108]	coref	19-17[166_108]
12-25	1645-1648	hpi	abstract[97]|abstract[101]|abstract[108]	new[97]|new[101]|new[108]	_	_
12-26	1649-1652	and	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-27	1653-1662	decreased	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-28	1663-1673	thereafter	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-29	1674-1675	,	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-30	1676-1681	which	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-31	1682-1684	is	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-32	1685-1694	different	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-33	1695-1699	from	abstract[97]|abstract[101]	new[97]|new[101]	_	_
12-34	1700-1703	the	abstract[97]|abstract[101]|abstract[109]	new[97]|new[101]|new[109]	coref	24-1[216_109]
12-35	1704-1711	results	abstract[97]|abstract[101]|abstract[109]	new[97]|new[101]|new[109]	_	_
12-36	1712-1717	shown	abstract[97]|abstract[101]|abstract[109]	new[97]|new[101]|new[109]	_	_
12-37	1718-1720	by	abstract[97]|abstract[101]|abstract[109]	new[97]|new[101]|new[109]	_	_
12-38	1721-1724	Cai	abstract[97]|abstract[101]|abstract[109]|person	new[97]|new[101]|new[109]|giv	_	_
12-39	1725-1727	et	abstract[97]|abstract[101]|abstract[109]	new[97]|new[101]|new[109]	_	_
12-40	1728-1730	al	abstract[97]|abstract[101]|abstract[109]|person	new[97]|new[101]|new[109]|giv	coref	29-3
12-41	1731-1735	that	abstract[97]|abstract[101]|abstract[109]	new[97]|new[101]|new[109]	_	_
12-42	1736-1739	the	abstract[97]|abstract[101]|abstract[109]|abstract[113]	new[97]|new[101]|new[109]|new[113]	_	_
12-43	1740-1744	mRNA	abstract[97]|abstract[101]|abstract[109]|abstract|abstract[113]	new[97]|new[101]|new[109]|new|new[113]	coref	22-13
12-44	1745-1750	level	abstract[97]|abstract[101]|abstract[109]|abstract[113]	new[97]|new[101]|new[109]|new[113]	_	_
12-45	1751-1753	of	abstract[97]|abstract[101]|abstract[109]|abstract[113]	new[97]|new[101]|new[109]|new[113]	_	_
12-46	1754-1760	IFN-λ1	abstract[97]|abstract[101]|abstract[109]|abstract[113]|abstract	new[97]|new[101]|new[109]|new[113]|new	coref	29-10
12-47	1761-1764	and	abstract[97]|abstract[101]|abstract[109]|abstract[113]	new[97]|new[101]|new[109]|new[113]	_	_
12-48	1765-1771	IFN-λ3	abstract[97]|abstract[101]|abstract[109]|abstract[113]|abstract[115]	new[97]|new[101]|new[109]|new[113]|new[115]	coref	23-16[0_115]
12-49	1772-1779	induced	abstract[97]|abstract[101]|abstract[109]|abstract[113]|abstract[115]	new[97]|new[101]|new[109]|new[113]|new[115]	_	_
12-50	1780-1782	by	abstract[97]|abstract[101]|abstract[109]|abstract[113]|abstract[115]	new[97]|new[101]|new[109]|new[113]|new[115]	_	_
12-51	1783-1789	wtCSFV	abstract[97]|abstract[101]|abstract[109]|abstract[113]|abstract[115]|abstract	new[97]|new[101]|new[109]|new[113]|new[115]|giv	coref	21-4
12-52	1790-1796	peaked	abstract[97]|abstract[101]|abstract[109]	new[97]|new[101]|new[109]	_	_
12-53	1797-1799	at	abstract[97]|abstract[101]|abstract[109]	new[97]|new[101]|new[109]	_	_
12-54	1800-1802	36	abstract[97]|abstract[101]|abstract[109]|abstract[117]	new[97]|new[101]|new[109]|new[117]	_	_
12-55	1803-1806	and	abstract[97]|abstract[101]|abstract[109]|abstract[117]	new[97]|new[101]|new[109]|new[117]	_	_
12-56	1807-1809	48	abstract[97]|abstract[101]|abstract[109]|abstract[117]	new[97]|new[101]|new[109]|new[117]	_	_
12-57	1810-1813	hpi	abstract[97]|abstract[101]|abstract[109]|abstract[117]	new[97]|new[101]|new[109]|new[117]	_	_
12-58	1814-1815	,	abstract[97]|abstract[101]|abstract[109]	new[97]|new[101]|new[109]	_	_
12-59	1816-1828	respectively	abstract[97]|abstract[101]|abstract[109]	new[97]|new[101]|new[109]	_	_
12-60	1829-1830	.	_	_	_	_

#Text=We speculate that the difference might be due to different cell types used .
13-1	1831-1833	We	person	giv	ana	19-1
13-2	1834-1843	speculate	_	_	_	_
13-3	1844-1848	that	_	_	_	_
13-4	1849-1852	the	abstract[119]	new[119]	_	_
13-5	1853-1863	difference	abstract[119]	new[119]	_	_
13-6	1864-1869	might	_	_	_	_
13-7	1870-1872	be	_	_	_	_
13-8	1873-1876	due	_	_	_	_
13-9	1877-1879	to	_	_	_	_
13-10	1880-1889	different	abstract[121]	new[121]	_	_
13-11	1890-1894	cell	object|abstract[121]	giv|new[121]	coref	14-8
13-12	1895-1900	types	abstract[121]	new[121]	_	_
13-13	1901-1905	used	abstract[121]	new[121]	_	_
13-14	1906-1907	.	_	_	_	_

#Text=Because CSFV causes enteric pathologies , a cell line from the intestines could be a good choice .
14-1	1908-1915	Because	_	_	_	_
14-2	1916-1920	CSFV	abstract	giv	coref	18-24
14-3	1921-1927	causes	_	_	_	_
14-4	1928-1935	enteric	abstract[123]	new[123]	_	_
14-5	1936-1947	pathologies	abstract[123]	new[123]	_	_
14-6	1948-1949	,	_	_	_	_
14-7	1950-1951	a	abstract[125]	new[125]	coref	14-15[127_125]
14-8	1952-1956	cell	object|abstract[125]	giv|new[125]	coref	15-3
14-9	1957-1961	line	abstract[125]	new[125]	_	_
14-10	1962-1966	from	abstract[125]	new[125]	_	_
14-11	1967-1970	the	abstract[125]|place[126]	new[125]|new[126]	_	_
14-12	1971-1981	intestines	abstract[125]|place[126]	new[125]|new[126]	_	_
14-13	1982-1987	could	_	_	_	_
14-14	1988-1990	be	_	_	_	_
14-15	1991-1992	a	abstract[127]	giv[127]	coref	15-1[130_127]
14-16	1993-1997	good	abstract[127]	giv[127]	_	_
14-17	1998-2004	choice	abstract[127]	giv[127]	_	_
14-18	2005-2006	.	_	_	_	_

#Text=The IPEC-J2 cell line was from non-transformed cells collected from the jejunum of a neonatal piglet and suitable for infection studies for enteropathogens .
15-1	2007-2010	The	abstract[130]	giv[130]	coref	17-3[146_130]
15-2	2011-2018	IPEC-J2	substance|abstract[130]	giv|giv[130]	coref	16-1
15-3	2019-2023	cell	object|abstract[130]	giv|giv[130]	coref	17-5
15-4	2024-2028	line	abstract[130]	giv[130]	_	_
15-5	2029-2032	was	_	_	_	_
15-6	2033-2037	from	_	_	_	_
15-7	2038-2053	non-transformed	object[131]	giv[131]	coref	19-14[165_131]
15-8	2054-2059	cells	object[131]	giv[131]	_	_
15-9	2060-2069	collected	object[131]	giv[131]	_	_
15-10	2070-2074	from	object[131]	giv[131]	_	_
15-11	2075-2078	the	object[131]|place[132]	giv[131]|new[132]	_	_
15-12	2079-2086	jejunum	object[131]|place[132]	giv[131]|new[132]	_	_
15-13	2087-2089	of	object[131]|place[132]	giv[131]|new[132]	_	_
15-14	2090-2091	a	object[131]|place[132]|animal[133]	giv[131]|new[132]|new[133]	_	_
15-15	2092-2100	neonatal	object[131]|place[132]|animal[133]	giv[131]|new[132]|new[133]	_	_
15-16	2101-2107	piglet	object[131]|place[132]|animal[133]	giv[131]|new[132]|new[133]	_	_
15-17	2108-2111	and	object[131]	giv[131]	_	_
15-18	2112-2120	suitable	object[131]	giv[131]	_	_
15-19	2121-2124	for	_	_	_	_
15-20	2125-2134	infection	event|abstract[135]	giv|new[135]	coref	23-1[204_0]
15-21	2135-2142	studies	abstract[135]	new[135]	_	_
15-22	2143-2146	for	abstract[135]	new[135]	_	_
15-23	2147-2162	enteropathogens	abstract[135]|animal	new[135]|new	_	_
15-24	2163-2164	.	_	_	_	_

#Text=IPEC-J2 exhibited robust expression of type III IFNs with a relatively lower type I IFNs response .
16-1	2165-2172	IPEC-J2	substance	giv	coref	17-4
16-2	2173-2182	exhibited	_	_	_	_
16-3	2183-2189	robust	abstract[138]	new[138]	_	_
16-4	2190-2200	expression	abstract[138]	new[138]	_	_
16-5	2201-2203	of	abstract[138]	new[138]	_	_
16-6	2204-2208	type	abstract[138]|abstract[139]|abstract[140]	new[138]|giv[139]|giv[140]	coref|coref	16-13[141_139]|16-15[0_140]
16-7	2209-2212	III	abstract[138]|abstract[139]|abstract[140]	new[138]|giv[139]|giv[140]	_	_
16-8	2213-2217	IFNs	abstract[138]|abstract[140]	new[138]|giv[140]	_	_
16-9	2218-2222	with	abstract[138]	new[138]	_	_
16-10	2223-2224	a	abstract[138]|abstract[143]	new[138]|giv[143]	coref	20-9[179_143]
16-11	2225-2235	relatively	abstract[138]|abstract[143]	new[138]|giv[143]	_	_
16-12	2236-2241	lower	abstract[138]|abstract[143]	new[138]|giv[143]	_	_
16-13	2242-2246	type	abstract[138]|abstract[141]|abstract[143]	new[138]|giv[141]|giv[143]	coref	18-26[157_141]
16-14	2247-2248	I	abstract[138]|abstract[141]|abstract[143]	new[138]|giv[141]|giv[143]	_	_
16-15	2249-2253	IFNs	abstract[138]|abstract|abstract[143]	new[138]|giv|giv[143]	coref	18-26[158_0]
16-16	2254-2262	response	abstract[138]|abstract[143]	new[138]|giv[143]	_	_
16-17	2263-2264	.	_	_	_	_

#Text=Thus , the IPEC-J2 cell line was chosen in this study .
17-1	2265-2269	Thus	_	_	_	_
17-2	2270-2271	,	_	_	_	_
17-3	2272-2275	the	abstract[146]	giv[146]	_	_
17-4	2276-2283	IPEC-J2	substance|abstract[146]	giv|giv[146]	coref	19-14
17-5	2284-2288	cell	object|abstract[146]	giv|giv[146]	_	_
17-6	2289-2293	line	abstract[146]	giv[146]	_	_
17-7	2294-2297	was	_	_	_	_
17-8	2298-2304	chosen	_	_	_	_
17-9	2305-2307	in	_	_	_	_
17-10	2308-2312	this	abstract[147]	giv[147]	_	_
17-11	2313-2318	study	abstract[147]	giv[147]	_	_
17-12	2319-2320	.	_	_	_	_

#Text=Cell lines or primary cultures from other intestinal areas or from adult pigs could be approached for further investigation of the interactions between CSFV and type III IFNs .
18-1	2321-2325	Cell	person|abstract[149]|abstract[150]	new|giv[149]|giv[150]	coref	18-1[150_149]
18-2	2326-2331	lines	abstract[149]|abstract[150]	giv[149]|giv[150]	_	_
18-3	2332-2334	or	abstract[150]	giv[150]	_	_
18-4	2335-2342	primary	abstract[150]|substance[151]	giv[150]|new[151]	_	_
18-5	2343-2351	cultures	abstract[150]|substance[151]	giv[150]|new[151]	_	_
18-6	2352-2356	from	abstract[150]|substance[151]	giv[150]|new[151]	_	_
18-7	2357-2362	other	abstract[150]|substance[151]|place[152]	giv[150]|new[151]|new[152]	_	_
18-8	2363-2373	intestinal	abstract[150]|substance[151]|place[152]	giv[150]|new[151]|new[152]	_	_
18-9	2374-2379	areas	abstract[150]|substance[151]|place[152]	giv[150]|new[151]|new[152]	_	_
18-10	2380-2382	or	_	_	_	_
18-11	2383-2387	from	_	_	_	_
18-12	2388-2393	adult	animal[153]	new[153]	_	_
18-13	2394-2398	pigs	animal[153]	new[153]	_	_
18-14	2399-2404	could	_	_	_	_
18-15	2405-2407	be	_	_	_	_
18-16	2408-2418	approached	_	_	_	_
18-17	2419-2422	for	_	_	_	_
18-18	2423-2430	further	abstract[154]	new[154]	_	_
18-19	2431-2444	investigation	abstract[154]	new[154]	_	_
18-20	2445-2447	of	abstract[154]	new[154]	_	_
18-21	2448-2451	the	abstract[154]|abstract[155]	new[154]|new[155]	_	_
18-22	2452-2464	interactions	abstract[154]|abstract[155]	new[154]|new[155]	_	_
18-23	2465-2472	between	abstract[154]|abstract[155]	new[154]|new[155]	_	_
18-24	2473-2477	CSFV	abstract[154]|abstract[155]|abstract	new[154]|new[155]|giv	coref	20-2
18-25	2478-2481	and	abstract[154]|abstract[155]	new[154]|new[155]	_	_
18-26	2482-2486	type	abstract[154]|abstract[155]|abstract[157]|abstract[158]	new[154]|new[155]|giv[157]|giv[158]	coref|coref	19-12[0_158]|19-37[172_157]
18-27	2487-2490	III	abstract[154]|abstract[155]|abstract[157]|abstract[158]	new[154]|new[155]|giv[157]|giv[158]	_	_
18-28	2491-2495	IFNs	abstract[154]|abstract[155]|abstract[158]	new[154]|new[155]|giv[158]	_	_
18-29	2496-2497	.	_	_	_	_

#Text=We found that the ∆Npro mutant induced significantly higher transcription of IFNs in IPEC-J2 cells from 24 to 48 hpi than its parental strain , suggesting that the Npro protein might be antagonistic to expression of type III IFNs .
19-1	2498-2500	We	person	giv	ana	20-15
19-2	2501-2506	found	_	_	_	_
19-3	2507-2511	that	_	_	_	_
19-4	2512-2515	the	animal[161]	giv[161]	ana	19-22[0_161]
19-5	2516-2521	∆Npro	person|animal[161]	new|giv[161]	_	_
19-6	2522-2528	mutant	animal[161]	giv[161]	_	_
19-7	2529-2536	induced	_	_	_	_
19-8	2537-2550	significantly	abstract[162]	giv[162]	_	_
19-9	2551-2557	higher	abstract[162]	giv[162]	_	_
19-10	2558-2571	transcription	abstract[162]	giv[162]	_	_
19-11	2572-2574	of	abstract[162]	giv[162]	_	_
19-12	2575-2579	IFNs	abstract[162]|abstract	giv[162]|giv	coref	19-37[174_0]
19-13	2580-2582	in	_	_	_	_
19-14	2583-2590	IPEC-J2	substance|object[165]	giv|giv[165]	coref|coref	21-16|21-16[192_165]
19-15	2591-2596	cells	object[165]	giv[165]	_	_
19-16	2597-2601	from	_	_	_	_
19-17	2602-2604	24	abstract[166]	giv[166]	_	_
19-18	2605-2607	to	abstract[166]	giv[166]	_	_
19-19	2608-2610	48	abstract[166]	giv[166]	_	_
19-20	2611-2614	hpi	abstract[166]	giv[166]	_	_
19-21	2615-2619	than	_	_	_	_
19-22	2620-2623	its	animal|abstract[168]	giv|giv[168]	_	_
19-23	2624-2632	parental	abstract[168]	giv[168]	_	_
19-24	2633-2639	strain	abstract[168]	giv[168]	_	_
19-25	2640-2641	,	_	_	_	_
19-26	2642-2652	suggesting	_	_	_	_
19-27	2653-2657	that	_	_	_	_
19-28	2658-2661	the	substance[170]	giv[170]	_	_
19-29	2662-2666	Npro	object|substance[170]	giv|giv[170]	coref	20-2[176_0]
19-30	2667-2674	protein	substance[170]	giv[170]	_	_
19-31	2675-2680	might	_	_	_	_
19-32	2681-2683	be	_	_	_	_
19-33	2684-2696	antagonistic	_	_	_	_
19-34	2697-2699	to	_	_	_	_
19-35	2700-2710	expression	abstract[171]	giv[171]	coref	26-3[236_171]
19-36	2711-2713	of	abstract[171]	giv[171]	_	_
19-37	2714-2718	type	abstract[171]|abstract[172]|abstract[174]	giv[171]|giv[172]|giv[174]	coref|coref	20-10[177_172]|20-24[184_174]
19-38	2719-2722	III	abstract[171]|abstract[172]|person|abstract[174]	giv[171]|giv[172]|giv|giv[174]	coref	25-4
19-39	2723-2727	IFNs	abstract[171]|abstract[174]	giv[171]|giv[174]	_	_
19-40	2728-2729	.	_	_	_	_

#Text=Because CSFV Npro has been found to subvert the type I IFN response , we speculated if Npro might have similar effect on type III IFNs .
20-1	2730-2737	Because	_	_	_	_
20-2	2738-2742	CSFV	abstract|object[176]	giv|giv[176]	coref|coref	20-18[0_176]|24-5
20-3	2743-2747	Npro	object[176]	giv[176]	_	_
20-4	2748-2751	has	_	_	_	_
20-5	2752-2756	been	_	_	_	_
20-6	2757-2762	found	_	_	_	_
20-7	2763-2765	to	_	_	_	_
20-8	2766-2773	subvert	_	_	_	_
20-9	2774-2777	the	abstract[179]	giv[179]	_	_
20-10	2778-2782	type	abstract[177]|abstract[179]	giv[177]|giv[179]	coref	20-24[183_177]
20-11	2783-2784	I	abstract[177]|abstract[179]	giv[177]|giv[179]	_	_
20-12	2785-2788	IFN	abstract|abstract[179]	giv|giv[179]	_	_
20-13	2789-2797	response	abstract[179]	giv[179]	_	_
20-14	2798-2799	,	_	_	_	_
20-15	2800-2802	we	person	giv	ana	21-1
20-16	2803-2813	speculated	_	_	_	_
20-17	2814-2816	if	_	_	_	_
20-18	2817-2821	Npro	object	giv	coref	21-19
20-19	2822-2827	might	_	_	_	_
20-20	2828-2832	have	_	_	_	_
20-21	2833-2840	similar	abstract[182]	new[182]	coref	21-22[195_182]
20-22	2841-2847	effect	abstract[182]	new[182]	_	_
20-23	2848-2850	on	abstract[182]	new[182]	_	_
20-24	2851-2855	type	abstract[182]|abstract[183]|abstract[184]	new[182]|giv[183]|giv[184]	coref|coref	21-12[0_183]|21-9[190_184]
20-25	2856-2859	III	abstract[182]|abstract[183]|abstract[184]	new[182]|giv[183]|giv[184]	_	_
20-26	2860-2864	IFNs	abstract[182]|abstract[184]	new[182]|giv[184]	_	_
20-27	2865-2866	.	_	_	_	_

#Text=We showed that wtCSFV strongly inhibited expression of poly(I : C)-induced type III IFNs in IPEC-J2 cells and Npro deletion abolished such an inhibitory effect .
21-1	2867-2869	We	person	giv	ana	22-1
21-2	2870-2876	showed	_	_	_	_
21-3	2877-2881	that	_	_	_	_
21-4	2882-2888	wtCSFV	abstract	giv	coref	23-4
21-5	2889-2897	strongly	_	_	_	_
21-6	2898-2907	inhibited	_	_	_	_
21-7	2908-2918	expression	abstract[187]	new[187]	coref	24-11[222_187]
21-8	2919-2921	of	abstract[187]	new[187]	_	_
21-9	2922-2928	poly(I	abstract[187]|abstract|abstract[190]	new[187]|new|giv[190]	coref|coref	22-16[203_190]|23-20[212_0]
21-10	2929-2930	:	abstract[187]|abstract[190]	new[187]|giv[190]	_	_
21-11	2931-2941	C)-induced	abstract[187]|abstract[190]	new[187]|giv[190]	_	_
21-12	2942-2946	type	abstract[187]|abstract|abstract[190]	new[187]|giv|giv[190]	coref	22-16[202_0]
21-13	2947-2950	III	abstract[187]|abstract[190]	new[187]|giv[190]	_	_
21-14	2951-2955	IFNs	abstract[187]|abstract[190]	new[187]|giv[190]	_	_
21-15	2956-2958	in	abstract[187]|abstract[190]	new[187]|giv[190]	_	_
21-16	2959-2966	IPEC-J2	abstract[187]|abstract[190]|substance|object[192]	new[187]|giv[190]|giv|giv[192]	coref|coref	23-23|23-20[215_192]
21-17	2967-2972	cells	abstract[187]|abstract[190]|object[192]	new[187]|giv[190]|giv[192]	_	_
21-18	2973-2976	and	_	_	_	_
21-19	2977-2981	Npro	object|event[194]	giv|new[194]	coref	22-5
21-20	2982-2990	deletion	event[194]	new[194]	_	_
21-21	2991-3000	abolished	_	_	_	_
21-22	3001-3005	such	abstract[195]	giv[195]	_	_
21-23	3006-3008	an	abstract[195]	giv[195]	_	_
21-24	3009-3019	inhibitory	abstract[195]	giv[195]	_	_
21-25	3020-3026	effect	abstract[195]	giv[195]	_	_
21-26	3027-3028	.	_	_	_	_

#Text=We further showed that Npro over-expression led to a marked reduction of mRNA transcripts of type III IFNs .
22-1	3029-3031	We	person	giv	ana	33-13
22-2	3032-3039	further	_	_	_	_
22-3	3040-3046	showed	_	_	_	_
22-4	3047-3051	that	_	_	_	_
22-5	3052-3056	Npro	object|abstract[198]	giv|new[198]	coref|coref	23-6[206_198]|23-8
22-6	3057-3072	over-expression	abstract[198]	new[198]	_	_
22-7	3073-3076	led	_	_	_	_
22-8	3077-3079	to	_	_	_	_
22-9	3080-3081	a	event[199]	new[199]	_	_
22-10	3082-3088	marked	event[199]	new[199]	_	_
22-11	3089-3098	reduction	event[199]	new[199]	_	_
22-12	3099-3101	of	event[199]	new[199]	_	_
22-13	3102-3106	mRNA	event[199]|abstract|abstract[201]	new[199]|giv|new[201]	_	_
22-14	3107-3118	transcripts	event[199]|abstract[201]	new[199]|new[201]	_	_
22-15	3119-3121	of	event[199]|abstract[201]	new[199]|new[201]	_	_
22-16	3122-3126	type	event[199]|abstract[201]|abstract[202]|abstract[203]	new[199]|new[201]|giv[202]|giv[203]	coref|coref	24-11[220_202]|24-13[0_203]
22-17	3127-3130	III	event[199]|abstract[201]|abstract[202]|abstract[203]	new[199]|new[201]|giv[202]|giv[203]	_	_
22-18	3131-3135	IFNs	event[199]|abstract[201]|abstract[203]	new[199]|new[201]|giv[203]	_	_
22-19	3136-3137	.	_	_	_	_

#Text=Either infection with wtCSFV or over-expression of Npro also resulted in significant reduction of the IFN-λ3 promoter activity of poly(I : C)-treated IPEC-J2 cells .
23-1	3138-3144	Either	event[204]	giv[204]	coref	30-11[261_204]
23-2	3145-3154	infection	event[204]	giv[204]	_	_
23-3	3155-3159	with	event[204]	giv[204]	_	_
23-4	3160-3166	wtCSFV	event[204]|abstract	giv[204]|giv	_	_
23-5	3167-3169	or	_	_	_	_
23-6	3170-3185	over-expression	abstract[206]	giv[206]	_	_
23-7	3186-3188	of	abstract[206]	giv[206]	_	_
23-8	3189-3193	Npro	abstract[206]|object	giv[206]|giv	coref	24-7[219_0]
23-9	3194-3198	also	_	_	_	_
23-10	3199-3207	resulted	_	_	_	_
23-11	3208-3210	in	_	_	_	_
23-12	3211-3222	significant	event[208]	new[208]	_	_
23-13	3223-3232	reduction	event[208]	new[208]	_	_
23-14	3233-3235	of	event[208]	new[208]	_	_
23-15	3236-3239	the	event[208]|abstract[211]	new[208]|new[211]	coref	34-15[295_211]
23-16	3240-3246	IFN-λ3	event[208]|abstract|abstract[211]	new[208]|giv|new[211]	coref	34-15
23-17	3247-3255	promoter	event[208]|person|abstract[211]	new[208]|new|new[211]	coref	34-16
23-18	3256-3264	activity	event[208]|abstract[211]	new[208]|new[211]	_	_
23-19	3265-3267	of	event[208]	new[208]	_	_
23-20	3268-3274	poly(I	event[208]|abstract[212]|object[215]	new[208]|giv[212]|giv[215]	coref	30-1[257_215]
23-21	3275-3276	:	event[208]|abstract[212]|object[215]	new[208]|giv[212]|giv[215]	_	_
23-22	3277-3287	C)-treated	event[208]|abstract[212]|abstract|object[215]	new[208]|giv[212]|new|giv[215]	_	_
23-23	3288-3295	IPEC-J2	event[208]|substance|object[215]	new[208]|giv|giv[215]	coref	33-27
23-24	3296-3301	cells	event[208]|object[215]	new[208]|giv[215]	_	_
23-25	3302-3303	.	_	_	_	_

#Text=These results demonstrate that CSFV employs its Npro to inhibit type III IFNs expression probably by targeting the regulatory elements involved in transcription of IFN-λs .
24-1	3304-3309	These	abstract[216]	giv[216]	_	_
24-2	3310-3317	results	abstract[216]	giv[216]	_	_
24-3	3318-3329	demonstrate	_	_	_	_
24-4	3330-3334	that	_	_	_	_
24-5	3335-3339	CSFV	abstract	giv	ana	24-7
24-6	3340-3347	employs	_	_	_	_
24-7	3348-3351	its	abstract|object[219]	giv|giv[219]	_	_
24-8	3352-3356	Npro	object[219]	giv[219]	_	_
24-9	3357-3359	to	_	_	_	_
24-10	3360-3367	inhibit	_	_	_	_
24-11	3368-3372	type	abstract[220]|abstract[222]	giv[220]|giv[222]	coref	25-3[227_220]
24-12	3373-3376	III	abstract[220]|abstract[222]	giv[220]|giv[222]	_	_
24-13	3377-3381	IFNs	abstract|abstract[222]	giv|giv[222]	coref	25-3[229_0]
24-14	3382-3392	expression	abstract[222]	giv[222]	_	_
24-15	3393-3401	probably	_	_	_	_
24-16	3402-3404	by	_	_	_	_
24-17	3405-3414	targeting	_	_	_	_
24-18	3415-3418	the	abstract[223]	new[223]	_	_
24-19	3419-3429	regulatory	abstract[223]	new[223]	_	_
24-20	3430-3438	elements	abstract[223]	new[223]	_	_
24-21	3439-3447	involved	abstract[223]	new[223]	_	_
24-22	3448-3450	in	abstract[223]	new[223]	_	_
24-23	3451-3464	transcription	abstract[223]|abstract[224]	new[223]|new[224]	_	_
24-24	3465-3467	of	abstract[223]|abstract[224]	new[223]|new[224]	_	_
24-25	3468-3474	IFN-λs	abstract[223]|abstract[224]|abstract	new[223]|new[224]|new	coref	30-7
24-26	3475-3476	.	_	_	_	_

#Text=Activation of type III IFNs , as the case with type I IFNs , requires IRF3 , IRF7 and NF-κB .
25-1	3477-3487	Activation	event[226]	new[226]	_	_
25-2	3488-3490	of	event[226]	new[226]	_	_
25-3	3491-3495	type	event[226]|abstract[227]|abstract[229]	new[226]|giv[227]|giv[229]	coref|coref	25-11[231_227]|25-11[232_229]
25-4	3496-3499	III	event[226]|abstract[227]|person|abstract[229]	new[226]|giv[227]|giv|giv[229]	coref	26-6
25-5	3500-3504	IFNs	event[226]|abstract[229]	new[226]|giv[229]	_	_
25-6	3505-3506	,	event[226]	new[226]	_	_
25-7	3507-3509	as	event[226]	new[226]	_	_
25-8	3510-3513	the	event[226]|abstract[230]	new[226]|new[230]	_	_
25-9	3514-3518	case	event[226]|abstract[230]	new[226]|new[230]	_	_
25-10	3519-3523	with	event[226]|abstract[230]	new[226]|new[230]	_	_
25-11	3524-3528	type	event[226]|abstract[230]|abstract[231]|abstract[232]	new[226]|new[230]|giv[231]|giv[232]	coref|coref	26-5[237_231]|26-5[239_232]
25-12	3529-3530	I	event[226]|abstract[230]|abstract[231]|abstract[232]	new[226]|new[230]|giv[231]|giv[232]	_	_
25-13	3531-3535	IFNs	event[226]|abstract[230]|abstract[232]	new[226]|new[230]|giv[232]	_	_
25-14	3536-3537	,	_	_	_	_
25-15	3538-3546	requires	_	_	_	_
25-16	3547-3551	IRF3	abstract	giv	_	_
25-17	3552-3553	,	_	_	_	_
25-18	3554-3558	IRF7	abstract	new	_	_
25-19	3559-3562	and	_	_	_	_
25-20	3563-3568	NF-κB	abstract	new	_	_
25-21	3569-3570	.	_	_	_	_

#Text=However , expression of type III IFNs does not need all components of the enhanceosome .
26-1	3571-3578	However	_	_	_	_
26-2	3579-3580	,	_	_	_	_
26-3	3581-3591	expression	abstract[236]	giv[236]	coref	29-9[256_236]
26-4	3592-3594	of	abstract[236]	giv[236]	_	_
26-5	3595-3599	type	abstract[236]|abstract[237]|abstract[239]	giv[236]|giv[237]|giv[239]	coref|coref	28-19[251_237]|32-7[268_239]
26-6	3600-3603	III	abstract[236]|abstract[237]|person|abstract[239]	giv[236]|giv[237]|giv|giv[239]	coref	33-8
26-7	3604-3608	IFNs	abstract[236]|abstract[239]	giv[236]|giv[239]	_	_
26-8	3609-3613	does	_	_	_	_
26-9	3614-3617	not	_	_	_	_
26-10	3618-3622	need	_	_	_	_
26-11	3623-3626	all	abstract[240]	new[240]	_	_
26-12	3627-3637	components	abstract[240]	new[240]	_	_
26-13	3638-3640	of	abstract[240]	new[240]	_	_
26-14	3641-3644	the	abstract[240]|abstract[241]	new[240]|new[241]	_	_
26-15	3645-3657	enhanceosome	abstract[240]|abstract[241]	new[240]|new[241]	_	_
26-16	3658-3659	.	_	_	_	_

#Text=IRF1 is a predominant antiviral molecule against many viruses .
27-1	3660-3664	IRF1	abstract	giv	coref	27-3[243_0]
27-2	3665-3667	is	_	_	_	_
27-3	3668-3669	a	abstract[243]	giv[243]	ana	28-1[0_243]
27-4	3670-3681	predominant	abstract[243]	giv[243]	_	_
27-5	3682-3691	antiviral	abstract[243]	giv[243]	_	_
27-6	3692-3700	molecule	abstract[243]	giv[243]	_	_
27-7	3701-3708	against	abstract[243]	giv[243]	_	_
27-8	3709-3713	many	abstract[243]|animal[244]	giv[243]|giv[244]	_	_
27-9	3714-3721	viruses	abstract[243]|animal[244]	giv[243]|giv[244]	_	_
27-10	3722-3723	.	_	_	_	_

#Text=It is the first identified member of the IRF family , but it does not induce production of type I IFNs .
28-1	3724-3726	It	abstract	giv	ana	28-13
28-2	3727-3729	is	_	_	_	_
28-3	3730-3733	the	person[246]	new[246]	_	_
28-4	3734-3739	first	person[246]	new[246]	_	_
28-5	3740-3750	identified	person[246]	new[246]	_	_
28-6	3751-3757	member	person[246]	new[246]	_	_
28-7	3758-3760	of	person[246]	new[246]	_	_
28-8	3761-3764	the	person[246]|abstract[248]	new[246]|new[248]	_	_
28-9	3765-3768	IRF	person[246]|person|abstract[248]	new[246]|new|new[248]	_	_
28-10	3769-3775	family	person[246]|abstract[248]	new[246]|new[248]	_	_
28-11	3776-3777	,	_	_	_	_
28-12	3778-3781	but	_	_	_	_
28-13	3782-3784	it	abstract	giv	coref	29-7
28-14	3785-3789	does	_	_	_	_
28-15	3790-3793	not	_	_	_	_
28-16	3794-3800	induce	_	_	_	_
28-17	3801-3811	production	abstract[250]	new[250]	_	_
28-18	3812-3814	of	abstract[250]	new[250]	_	_
28-19	3815-3819	type	abstract[250]|abstract[251]	new[250]|giv[251]	coref	32-7[267_251]
28-20	3820-3821	I	abstract[250]|abstract[251]	new[250]|giv[251]	_	_
28-21	3822-3826	IFNs	abstract[250]	new[250]	_	_
28-22	3827-3828	.	_	_	_	_

#Text=Odendall et al has shown that IRF1 regulates peroxisome-mediated IFN-λ1 expression .
29-1	3829-3837	Odendall	person	new	_	_
29-2	3838-3840	et	_	_	_	_
29-3	3841-3843	al	person	giv	_	_
29-4	3844-3847	has	_	_	_	_
29-5	3848-3853	shown	_	_	_	_
29-6	3854-3858	that	_	_	_	_
29-7	3859-3863	IRF1	abstract	giv	coref	33-11
29-8	3864-3873	regulates	_	_	_	_
29-9	3874-3893	peroxisome-mediated	abstract[256]	giv[256]	_	_
29-10	3894-3900	IFN-λ1	abstract|abstract[256]	giv|giv[256]	_	_
29-11	3901-3911	expression	abstract[256]	giv[256]	_	_
29-12	3912-3913	.	_	_	_	_

#Text=Epithelial cells have preference of producing IFN-λs over IFN-α/β upon viral infection .
30-1	3914-3924	Epithelial	object[257]	giv[257]	coref	31-12[265_257]
30-2	3925-3930	cells	object[257]	giv[257]	_	_
30-3	3931-3935	have	_	_	_	_
30-4	3936-3946	preference	abstract[258]	new[258]	_	_
30-5	3947-3949	of	abstract[258]	new[258]	_	_
30-6	3950-3959	producing	abstract[258]	new[258]	_	_
30-7	3960-3966	IFN-λs	abstract[258]|abstract	new[258]|giv	coref	34-12[291_0]
30-8	3967-3971	over	abstract[258]	new[258]	_	_
30-9	3972-3979	IFN-α/β	abstract[258]|abstract	new[258]|new	_	_
30-10	3980-3984	upon	abstract[258]	new[258]	_	_
30-11	3985-3990	viral	abstract[258]|event[261]	new[258]|giv[261]	ana	31-1[0_261]
30-12	3991-4000	infection	abstract[258]|event[261]	new[258]|giv[261]	_	_
30-13	4001-4002	.	_	_	_	_

#Text=This may be due to relatively higher expression of peroxisomes in epithelial cells .
31-1	4003-4007	This	event	giv	_	_
31-2	4008-4011	may	_	_	_	_
31-3	4012-4014	be	_	_	_	_
31-4	4015-4018	due	_	_	_	_
31-5	4019-4021	to	_	_	_	_
31-6	4022-4032	relatively	abstract[263]	new[263]	coref	33-19[281_263]
31-7	4033-4039	higher	abstract[263]	new[263]	_	_
31-8	4040-4050	expression	abstract[263]	new[263]	_	_
31-9	4051-4053	of	abstract[263]	new[263]	_	_
31-10	4054-4065	peroxisomes	abstract[263]|substance	new[263]|new	_	_
31-11	4066-4068	in	abstract[263]	new[263]	_	_
31-12	4069-4079	epithelial	abstract[263]|object[265]	new[263]|giv[265]	coref	33-27[286_265]
31-13	4080-4085	cells	abstract[263]|object[265]	new[263]|giv[265]	_	_
31-14	4086-4087	.	_	_	_	_

#Text=Peroxisomal MAVS is known to induce type III IFNs , as opposed to induction of type I IFNs via mitochondrial MAVS .
32-1	4088-4099	Peroxisomal	abstract[266]	new[266]	coref	32-20[272_266]
32-2	4100-4104	MAVS	abstract[266]	new[266]	_	_
32-3	4105-4107	is	_	_	_	_
32-4	4108-4113	known	_	_	_	_
32-5	4114-4116	to	_	_	_	_
32-6	4117-4123	induce	_	_	_	_
32-7	4124-4128	type	abstract[267]|abstract[268]	giv[267]|giv[268]	coref|coref	32-16[270_267]|32-16[271_268]
32-8	4129-4132	III	abstract[267]|abstract[268]	giv[267]|giv[268]	_	_
32-9	4133-4137	IFNs	abstract[268]	giv[268]	_	_
32-10	4138-4139	,	_	_	_	_
32-11	4140-4142	as	_	_	_	_
32-12	4143-4150	opposed	_	_	_	_
32-13	4151-4153	to	_	_	_	_
32-14	4154-4163	induction	event[269]	new[269]	_	_
32-15	4164-4166	of	event[269]	new[269]	_	_
32-16	4167-4171	type	event[269]|abstract[270]|abstract[271]	new[269]|giv[270]|giv[271]	coref|coref	33-7[274_270]|33-7[276_271]
32-17	4172-4173	I	event[269]|abstract[270]|abstract[271]	new[269]|giv[270]|giv[271]	_	_
32-18	4174-4178	IFNs	event[269]|abstract[271]	new[269]|giv[271]	_	_
32-19	4179-4182	via	event[269]	new[269]	_	_
32-20	4183-4196	mitochondrial	event[269]|abstract[272]	new[269]|giv[272]	_	_
32-21	4197-4201	MAVS	event[269]|abstract[272]	new[269]|giv[272]	_	_
32-22	4202-4203	.	_	_	_	_

#Text=To better understand the regulation of type III IFNs by IRF1 , we attempted to regulate levels of IRF1 expression by overexpression or RNA interference in IPEC-J2 cells .
33-1	4204-4206	To	_	_	_	_
33-2	4207-4213	better	_	_	_	_
33-3	4214-4224	understand	_	_	_	_
33-4	4225-4228	the	abstract[273]	new[273]	_	_
33-5	4229-4239	regulation	abstract[273]	new[273]	_	_
33-6	4240-4242	of	abstract[273]	new[273]	_	_
33-7	4243-4247	type	abstract[273]|abstract[274]|abstract[276]	new[273]|giv[274]|giv[276]	coref|coref	34-33[301_274]|34-33[303_276]
33-8	4248-4251	III	abstract[273]|abstract[274]|person|abstract[276]	new[273]|giv[274]|giv|giv[276]	coref	34-34
33-9	4252-4256	IFNs	abstract[273]|abstract[276]	new[273]|giv[276]	_	_
33-10	4257-4259	by	abstract[273]	new[273]	_	_
33-11	4260-4264	IRF1	abstract[273]|abstract	new[273]|giv	coref	33-19
33-12	4265-4266	,	_	_	_	_
33-13	4267-4269	we	person	giv	_	_
33-14	4270-4279	attempted	_	_	_	_
33-15	4280-4282	to	_	_	_	_
33-16	4283-4291	regulate	_	_	_	_
33-17	4292-4298	levels	abstract[279]	new[279]	_	_
33-18	4299-4301	of	abstract[279]	new[279]	_	_
33-19	4302-4306	IRF1	abstract[279]|abstract|abstract[281]	new[279]|giv|giv[281]	coref	34-3
33-20	4307-4317	expression	abstract[279]|abstract[281]	new[279]|giv[281]	_	_
33-21	4318-4320	by	_	_	_	_
33-22	4321-4335	overexpression	abstract	new	_	_
33-23	4336-4338	or	_	_	_	_
33-24	4339-4342	RNA	organization|abstract[284]	new|new[284]	_	_
33-25	4343-4355	interference	abstract[284]	new[284]	_	_
33-26	4356-4358	in	abstract[284]	new[284]	_	_
33-27	4359-4366	IPEC-J2	abstract[284]|substance|object[286]	new[284]|giv|giv[286]	_	_
33-28	4367-4372	cells	abstract[284]|object[286]	new[284]|giv[286]	_	_
33-29	4373-4374	.	_	_	_	_

#Text=Overexpression of IRF1 led to a significant increase of transcription of all IFN-λs and IFN-λ3 promoter activity , while gene silencing showed opposite effects , indicating that IRF1 positively regulates expression of type III IFNs .
34-1	4375-4389	Overexpression	event[287]	new[287]	_	_
34-2	4390-4392	of	event[287]	new[287]	_	_
34-3	4393-4397	IRF1	event[287]|abstract	new[287]|giv	coref	34-28
34-4	4398-4401	led	_	_	_	_
34-5	4402-4404	to	_	_	_	_
34-6	4405-4406	a	event[289]	new[289]	_	_
34-7	4407-4418	significant	event[289]	new[289]	_	_
34-8	4419-4427	increase	event[289]	new[289]	_	_
34-9	4428-4430	of	event[289]	new[289]	_	_
34-10	4431-4444	transcription	event[289]|abstract[290]	new[289]|new[290]	_	_
34-11	4445-4447	of	event[289]|abstract[290]	new[289]|new[290]	_	_
34-12	4448-4451	all	event[289]|abstract[290]|abstract[291]|abstract[292]	new[289]|new[290]|giv[291]|giv[292]	coref	34-12[292_291]
34-13	4452-4458	IFN-λs	event[289]|abstract[290]|abstract[291]|abstract[292]	new[289]|new[290]|giv[291]|giv[292]	_	_
34-14	4459-4462	and	event[289]|abstract[290]|abstract[292]	new[289]|new[290]|giv[292]	_	_
34-15	4463-4469	IFN-λ3	event[289]|abstract[290]|abstract[292]|abstract|abstract[295]	new[289]|new[290]|giv[292]|giv|giv[295]	_	_
34-16	4470-4478	promoter	event[289]|abstract[290]|abstract[292]|person|abstract[295]	new[289]|new[290]|giv[292]|giv|giv[295]	_	_
34-17	4479-4487	activity	event[289]|abstract[290]|abstract[292]|abstract[295]	new[289]|new[290]|giv[292]|giv[295]	_	_
34-18	4488-4489	,	_	_	_	_
34-19	4490-4495	while	_	_	_	_
34-20	4496-4500	gene	abstract|abstract[297]	new|new[297]	_	_
34-21	4501-4510	silencing	abstract[297]	new[297]	_	_
34-22	4511-4517	showed	_	_	_	_
34-23	4518-4526	opposite	abstract[298]	new[298]	_	_
34-24	4527-4534	effects	abstract[298]	new[298]	_	_
34-25	4535-4536	,	_	_	_	_
34-26	4537-4547	indicating	_	_	_	_
34-27	4548-4552	that	_	_	_	_
34-28	4553-4557	IRF1	abstract	giv	_	_
34-29	4558-4568	positively	_	_	_	_
34-30	4569-4578	regulates	_	_	_	_
34-31	4579-4589	expression	abstract[300]	new[300]	_	_
34-32	4590-4592	of	abstract[300]	new[300]	_	_
34-33	4593-4597	type	abstract[300]|abstract[301]|abstract[303]	new[300]|giv[301]|giv[303]	_	_
34-34	4598-4601	III	abstract[300]|abstract[301]|person|abstract[303]	new[300]|giv[301]|giv|giv[303]	_	_
34-35	4602-4606	IFNs	abstract[300]|abstract[303]	new[300]|giv[303]	_	_
34-36	4607-4608	.	_	_	_	_
